glp 1 pathophysiology Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic GLP-1 Receptor Agonists as Treatments

Peripheral but not central administration of GLP-1 fails to inhibit angiotensin (ANG) II-induced drinking in rats that have been treated with monosodium glutamate (MSG) to induce damage of the ARC and the sensory circumventricular organs, suggesting that peripherally administered GLP-1 effects drinking behavior via CNS-dependent mechanisms [760]

, Optimization of Co-Agonism at GLP-1 and Glucagon Receptors to Safely Maximize Weight Reduction in DIO-Rodents, Biopolymers 98, no

The degree of weight loss achieved also matterspatients who reach a healthy weight range and maintain it for an extended period while on medication may attempt discontinuation differently than those who achieve modest weight reduction

Safety info : GLP-1 medications are used to treat obesity or overweight (with weight-related problems), along with diet and exercise

[14] Ard J, Fitch A, Fruh S, et al

Ozempic/Wegovy) Semaglutide is a GLP-1 receptor agonist (used in medicine for diabetes and/or chronic weight management, depending on product and jurisdiction